Search

Your search keyword '"Ji-Lian Cai"' showing total 10 results
Start Over Author "Ji-Lian Cai" Publisher elsevier bv
10 results on '"Ji-Lian Cai"'

1. Results of a Phase 2 Trial of Allogeneic Hematopoietic Stem Cell Transplantation using 90Y-Ibritumomab Tiuxetan (Zevalin®) in Combination with Fludarabine and Melphalan in Patients with High-Risk B-Cell Non-Hodgkin's Lymphoma

Author

Matthew Mei, Joycelynne Palmer, Nicole Ni-Chun Tsai, Jennifer Simpson, James O'Hearn, Anthony Stein, Stephen Forman, Ricardo Spielberger, Ji-Lian Cai, Myo Htut, Ryotaro Nakamura, Monzr M Al Malki, Alex Herrera, Jeffrey Wong, and Auayporn Nademanee

Subjects
Cancer Research, Oncology, Hematology
Published
2023
Full Text
View/download PDF

2. Real-World Outcomes of CD19 CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Diffuse Large B-Cell Lymphoma

Author

Swetha Kambhampati, Leslie Popplewell, Yan Wang, Matthew Mei, Liana Nikolaenko, Geoffrey Shouse, Alex F. Herrera, Jasmine Zain, Tanya Siddiqi, James Godfrey, Dr. John H Baird, Steven Rosen, Alexey V. Danilov, Ji-Lian Cai, Ricardo Spielberger, Joycelynne Palmer, Annette Brown, Larry W. Kwak, Eileen Smith, Stephen J. Forman, and L. Elizabeth E. Budde

Subjects
Transplantation, Molecular Medicine, Immunology and Allergy, Cell Biology, Hematology
Published
2023
Full Text
View/download PDF

3. Peri-Transplant Administration of Ruxolitinib (Rux) in Patients with Myelofibrosis (MF) Is Safe and Effective. A Pilot Study

Author

Timothy W. Synold, Haris Ali, Vinod Pullarkat, Matthew Mei, Ryotaro Nakamura, Stephen J. Forman, David S. Snyder, Ni-Chun Tsia, Syed Rahmanuddin, Sally Mokhtari, Ji-Lian Cai, Joycelynne Palmer, and Amandeep Salhotra

Subjects
Transplantation, medicine.medical_specialty, Ruxolitinib, business.industry, Peri, Cell Biology, Hematology, medicine.disease, Internal medicine, Molecular Medicine, Immunology and Allergy, Medicine, In patient, business, Myelofibrosis, Administration (government), medicine.drug
Published
2021
Full Text
View/download PDF

4. ALL-440: Promising Safety and Efficacy Results from an Ongoing Phase 1/2 Study of Pembrolizumab in Combination with Blinatumomab in Patients (pts) with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Author

Jianying Zhang, Ibrahim Aldoss, Paul Koller, L. Elizabeth Budde, Ahmed Aribi, Karamjeet S. Sandhu, Ji-Lian Cai, Sandra H. Thomas, Ricardo Spielberger, Guido Marcucci, Quy Huynh-Tran, Joycelynne Palmer, Anthony S. Stein, Elise Elise Cooper, Marjorie A. Robbins, Ni-Chun Tsai, Mathew Mei, and Amandeep Salhotra

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Side effect, business.industry, Lymphoblastic Leukemia, Hematology, Pembrolizumab, medicine.disease, Cytokine release syndrome, Refractory, Internal medicine, Toxicity, medicine, In patient, Blinatumomab, business, medicine.drug
Abstract

Background: Blinatumomab, a bispecific anti-CD19/CD3 antibody, demonstrated single-agent efficacy with 42% CR/CRh in R/R B-ALL. Upregulation of immune inhibitory molecules has been shown to confer resistance to blinatumomab. Here, we set out to test the combination of pembrolizumab and blinatumomab in a phase 1/2 trial (NCT03512405). Methods: Pts [≥18 years old (yo); ECOG Results: As of February 1, 2021, 7 pts were enrolled to phase 1, with one unevaluable. Six treated and evaluable pts received a median of 2 (1–5) cycles of treatment. At baseline, the median age was 51 yo (29–74) with median 2 (2–4) prior lines of regimens and median 29% (0–83) BM blasts. Two pts had extramedullary disease. In cycle 1, all 6 pts experienced grade (gr) 1–2 cytokine release syndrome. Neurologic toxicities were all reversible with only 1 ≥ gr3 AE. All-non-hematologic gr3 toxicities, were reversible. No dose-limiting toxicity, ≥ gr4 non-hematologic toxicity, or treatment-related deaths were seen. Five of 6 evaluable pts (83%) achieved MRD-negative CR after a median of 1 (1–2) cycle. Three pts in CR received alloHCT, all engrafted. With a median follow-up of 2.8 (1.1–9.6) months, 4 CRs are ongoing (1 post-transplant), and 5 of 6 pts are still alive at the data cut-off. Conclusions: The combination of pembrolizumab and blinatumomab in phase 1 of this study in pts with B-ALL was deemed safe with a manageable side effect profile and encouraging anti-leukemic activity. The study is now open for phase 2 with the primary objective of overall response rate.

Published
2021
Full Text
View/download PDF

5. Poster: ALL-440: Promising Safety and Efficacy Results from an Ongoing Phase 1/2 Study of Pembrolizumab in Combination with Blinatumomab in Patients (pts) with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Author

Karamjeet S. Sandhu, Quy Huynh-Tran, Elise Elise Cooper, Jianying Zhang, Joycelynne Palmer, Ni-Chun Tsai, Sandra Thomas, Marjorie Robbins, Ahmed Aribi, Amandeep Salhotra, Mathew Mei, Ji-Lian Cai, Ricardo Spielberger, Paul Koller, Ibrahim Aldoss, Anthony Stein, Guido Marcucci, and L. Elizabeth Budde

Subjects
Cancer Research, Oncology, Hematology
Published
2021
Full Text
View/download PDF

6. Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis

Author

Joseph C. Alvarnas, Ji-Lian Cai, Joycelynne Palmer, Anthony S. Stein, David S. Snyder, Sandra H. Thomas, Rodrigo Maegawa, Tracey Stiller, Ryotaro Nakamura, Vinod Pullarkat, Ravi Bhatia, Margaret R. O'Donnell, Karen Chang, Pablo M. Parker, Shirong Wang, David Senitzer, Joseph Chao, and Stephen J. Forman

Subjects
Adult, Male, Melphalan, Cancer Research, medicine.medical_specialty, Transplantation Conditioning, medicine.medical_treatment, Graft vs Host Disease, chemical and pharmacologic phenomena, Hematopoietic stem cell transplantation, Chemoprevention, Gastroenterology, Article, Tacrolimus, Young Adult, immune system diseases, Internal medicine, medicine, Humans, Transplantation, Homologous, Cumulative incidence, Aged, Retrospective Studies, Sirolimus, Dose-Response Relationship, Drug, business.industry, Incidence, Hematopoietic Stem Cell Transplantation, Hematology, Middle Aged, Survival Analysis, Surgery, Fludarabine, Transplantation, Drug Combinations, surgical procedures, operative, Oncology, Myelodysplastic Syndromes, Female, business, Immunosuppressive Agents, Vidarabine, medicine.drug
Abstract

We report a consecutive series of 59 patients with MDS who underwent reduced-intensity hematopoietic stem cell transplantation (RI-HSCT) with fludarabine/melphalan conditioning and tacrolimus/sirolimus-based GVHD prophylaxis. Two-year OS, EFS, and relapse incidences were 75.1%, 65.2%, and 20.9%, respectively. The cumulative incidence of non-relapse mortality at 100 days, 1 year, and 2 years was 3.4%, 8.5%, and 10.5%, respectively. The incidence of grade II-IV acute GVHD was 35.4%; grade III-IV was 18.6%. Forty of 55 evaluable patients developed chronic GVHD; of these 35 were extensive grade. This RI-HSCT protocol produces encouraging outcomes in MDS patients, and tacrolimus/sirolimus-based GVHD prophylaxis may contribute to that promising result.

Published
2012
Full Text
View/download PDF

7. Does Adding Zevalin® to Reduced Intensity Regimen (RIC) of Fludarabine and Melphalan Improve Outcome of Patients with Relapsed/Refractory B-Cell Lymphoma Who Were Chemoresistant and FDG PET Positive at the Time of Allo-HCT?

Author

Andrew Raubitschek, Ji-Lian Cai, Firoozeh Sahebi, Auayporn Nademanee, Jennifer Simpson, Leslie Popplewell, Joycelynne Palmer, Tracey Stiller, Robert T. Chen, and Stephen J. Forman

Subjects
Oncology, Melphalan, Transplantation, medicine.medical_specialty, business.industry, Reduced intensity, Hematology, medicine.disease, Surgery, Fludarabine, Regimen, Internal medicine, Relapsed refractory, medicine, business, B-cell lymphoma, medicine.drug
Published
2016
Full Text
View/download PDF

8. 378: Tacrolimus, Sirolimus and Antithymocyte Globulin (rATG) for Graft Versus Host Disease Prophylaxis for Unrelated Donor Hematopoietic Cell Transplantation

Author

Adrienne D. Briggs, Ji-Lian Cai, Pablo M. Parker, Joseph Rosenthal, Vinod Pullarkat, Ryotaro Nakamura, A P Nademanee, S.J. Forman, David Senitzer, O.S. Aljitawi, David S. Snyder, Joycelynne Palmer, and J. Schriber

Subjects
Transplantation, Globulin, biology, Hematopoietic cell, business.industry, Hematology, medicine.disease, Tacrolimus, Graft-versus-host disease, Unrelated Donor, Sirolimus, Immunology, biology.protein, Medicine, business, medicine.drug
Published
2008
Full Text
View/download PDF

9. Sirolimus, Tacrolimus, and rabbit ATG (r-ATG) as Graft-Versus-Host Disease Prophylaxis in Patients Undergoing Unrelated Donor Peripheral Blood Hematopoietic Cell Transplant (HCT): Extended Follow Up and Updated Analysis

Author

Ji-Lian Cai, A P Nademanee, Vinod Pullarkat, David S. Snyder, Joycelynne Palmer, Samer K. Khaled, Ryotaro Nakamura, S.J. Forman, David Senitzer, and Pablo M. Parker

Subjects
Transplantation, Hematopoietic cell, business.industry, Hematology, medicine.disease, Tacrolimus, Peripheral blood, Graft-versus-host disease, Unrelated Donor, Sirolimus, Immunology, Medicine, In patient, Rabbit ATG, business, medicine.drug
Published
2011
Full Text
View/download PDF

10. Sirolimus, Tacrolimus, And Rabbit ATG (rATG) As Graft-Versus-Host Prophylaxis In Patients Undergoing Unrelated Donor Hematopoietic Stem Cell Transplant (HCT)

Author

Chatchada Karanes, Ji-Lian Cai, Vinod Pullarkat, Pablo M. Parker, Joycelynne Palmer, David S. Snyder, Ryotaro Nakamura, S.J. Forman, Samer K. Khaled, A P Nademanee, and David Senitzer

Subjects
Transplantation, Host (biology), business.industry, Hematopoietic stem cell, Hematology, Tacrolimus, medicine.anatomical_structure, Unrelated Donor, Sirolimus, Immunology, medicine, In patient, Rabbit ATG, business, medicine.drug
Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results